Loading stock data…
Alector, Inc. (ALEC)
$2.01+0.15 (+8.06%)
Market OpenUpdated 3:08 PM EDT
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alector, Inc. in the Healthcare sector is trading at $1.92 with a market capitalization of $240M. Wall Street consensus targets $3.10 (5 analysts), implying a +61.5% move over the next 12 months. The stock is currently 44% below its 52-week high of $3.40, remaining 5.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +61.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.05M↓ | $6.24M↑ | $3.26M↓ | $7.87M↑ | $3.67M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$24.92M↑ | -$39.57M↓ | -$37.61M↓ | -$34.14M↑ | -$44.70M |
| Net Income | -$22.93M↑ | -$37.27M↓ | -$34.67M↓ | -$30.52M↑ | -$40.47M |
Peer Comparison
JNJUNHPFE
Fundamentals
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treatin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$239.81M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.65
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1207.74%
Volume
Today's trading volume
355,906
Recent News
Alector (ALEC) Stock Faces Mixed Analyst Target Changes On Tau Therapy Readthrough
Alector’s latest update leaves the model fair value steady at US$3.10 per share, so headline price target assumptions are unchanged even as inputs inside the model continue to move. Analysts are linking this steady fair value to shifting sentiment around tau-targeting therapies in Alzheimer’s, where the CELIA dataset and broader MAPT readthroughs are feeding directly into how they weigh upside potential against execution risk. As you read on, you will see how these crosscurrents shape the...
How The Alector (ALEC) Investment Story Is Shifting With Tau Readthroughs And BBB Shuttle Focus
Alector’s updated analyst framework now points to a fair value move from US$2.88 to US$3.10, a modest shift that still signals a meaningful recalibration of expectations. This change is closely tied to how analysts are weighing CELIA’s readthrough for tau-targeting therapies and Alector’s pivot toward blood brain barrier shuttle based designs, balancing the scientific promise against execution risks and the memory of prior trial setbacks. As you read on, you will see how to track these moving...
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
Alector (ALEC) delivered earnings and revenue surprises of +40.00% and -65.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alkermes (ALKS) Reports Q1 Loss, Beats Revenue Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of +30.31% and +9.50%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?